Takeaway
- Among high-risk vaccinated patients with COVID-19, nirmatrelvir/ritonavir substantially reduces risk for death or severe disease in the real world.
- Adequate vaccination status is even more protective.
Why this matters
- Nirmatrelvir/ritonavir received emergency use authorization based on interim analysis of the EPIC-HR trial, which was conducted before the Omicron era....
